Trial
NCT02533323
P-Gemox Regimen as First-line Chemotherapy in NK/T Lymphoma Patiens
Phase IITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Sun Yat-sen University
Collaborators
—
Condition
Lymphoma, Extranodal NK-T-Cell
Intervention
gemcitabine
Why stopped
—
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2018-05-09